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SUMMARY
Although the importance of reactive astrocytes dur-
ing CNS pathology is well established, the function
of astroglia in adult CNS homeostasis is less well
understood. With the use of conditional, astrocyte-
restricted protein synthesis termination, we found
that selective paralysis of GFAP+ astrocytes in vivo
led to rapid neuronal cell loss and severe motor def-
icits. This occurredwhile structural astroglial support
still persisted and in the absence of any major micro-
vascular damage.Whereas loss of astrocyte function
did lead to microglial activation, this had no impact
on the neuronal loss and clinical decline. Neuronal
injury was caused by oxidative stress resulting from
the reduced redox scavenging capability of dysfunc-
tional astrocytes and could be prevented by the
in vivo treatment with scavengers of reactive oxygen
and nitrogen species (ROS/RNS). Our results sug-
gest that the subpopulation of GFAP+ astrocytes
maintain neuronal health by controlling redox ho-
meostasis in the adult CNS.
INTRODUCTION
Astrocytes are specialized glial cells of the CNS that vastly
outnumber neurons. Different astrocyte subtypes have been
described, of which some express the cytoskeletal protein glial
fibrillary acidic protein (GFAP). GFAP+ astrocytes extend many
long fiber-like processes, which form gap junctions between
neighboring astrocytes, contact synapses, and nodes of Ranv-
ier, and surround blood vessels. Astrocytes likely are important
contributors to neurodegenerative disease such as familial
amyotrophic lateral sclerosis (Haidet-Phillips et al., 2011) or
certain types of leukodystrophies. But it has also been proposed
that they have essential functions in the healthy CNS, including
the maintenance of neuronal homeostasis, the regulation of syn-
aptic transmission, and the formation of the neurovascular unit
(reviewed in Allen and Barres, 2009 and Sofroniew and Vinters,
2010). Much of what we know about astrocyte function has
come from in vitro studies using isolated glial cells or slice cul-
tures, where they among others promote growth and survival
of neurons (Banker, 1980). More-recent studies have shown
that astrocytes can also support CNSmyelination in multiple cul-
ture models (Sorensen et al., 2008). However, gene targeting of
astrocyte intermediate filament genes like GFAP and vimentin
resulted in no gross neurological, behavioral, or structural CNS
abnormalities in vivo (Colucci-Guyon et al., 1994; Pekny et al.,
1995). Reactive astrocytes have been specifically depleted dur-
ing scar formation using the GFAP-HSV-TK model, resulting in
exacerbated traumatic brain injury, whereas it also improved
nerve fiber outgrowth (Bush et al., 1999). Furthermore, diphtheria
toxin (DT)-A-mediated astrocyte depletion has revealed astro-
glial regulation of synaptogenesis in the developing nervous sys-
tem (Tsai et al., 2012).
In the present study, we sought to use genetic strategies for
selective in vivo paralysis and depletion to interrogate the pro-
posed functional contribution of GFAP+ astrocytes to tissue ho-
meostasis in the adult CNS.
RESULTS
Inducible Paralysis of Adult GFAP+ Astrocytes In Vivo
In order to study the role of astrocytes under physiological con-
ditions in adult mice in vivo, we used two different models of
astrocyte targeting: we crossed mice in which expression of
the DT receptor (DTR) from an ubiquitously active promoter is
prevented by a loxP-flanked stop cassette (iDTR; Buch et al.,
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2005) with transgenic mice expressing the Cre recombinase un-
der the control of theGFAPpromoter (GFAPCre:iDTR; FigureS1).
This led to DTR expression selectively by GFAP+ astrocytes. DT
is a toxin that, upon entry into the cytoplasm, ‘‘paralyzes’’ target
cells by catalyzing the inactivation of elongation factor 2, result-
ing in termination of protein synthesis and subsequent cell death
(Honjo et al., 1971).
Because glial cells are the progenitors for neurogenesis during
brain development, some GFAP+ precursors might have under-
gone irreversible recombination, leading to inadvertent expres-
sion of DTR in mature neurons of GFAP:iDTR mice. Bajenaru
et al. (2002) reported that the GFAPCre strain used here does
not induce any obvious neuronal expression of a loxP-flanked
transgene. However, to definitively rule out potential, neuronal
DTR expression, we used a second model, by which tamox-
ifen-inducible Cre-ERT2 allows temporarily precise postnatal in-
duction of DTA expression in adult astrocytes (GFAPCreERT2:
DTA; Hirrlinger et al., 2006; Ivanova et al., 2005; Figure 1A).
As the most-pronounced pathology in tamoxifen-treated
GFAPCreERT2:DTA mice was found in the cervical spinal cord,
our subsequent analysis focused on this region. We confirmed
the specificity of this genetic targeting approach by flow cytom-
etry and immunohistochemical analysis of GFAPCreERT2 mice
crossed to a Rosa26-tdTomato reporter mouse line (Figures
1B and S2). In the spinal cord, the Cre-recombinase was primar-
ily active in the subpopulation of GFAP+ astrocytes (79% ± 3.6%
of which were tdTomato+; n = 6 mice), whereas only a smaller
fraction of astrocytes (23% ± 2.5% of which were tdTomato+;
n = 6 mice) labeled with the more-abundant marker S100+
were targeted (Figure 1B). Our results further showed that, at
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Figure 1. Paralysis of Astrocytes in GFAP-
CreERT2:DTA Mice Leads to a Rapid and
Severe Neuronal Motor Phenotype
(A) Schematic diagram of GFAPCreERT2 3 DTA
(GFAPCreERT2:DTA) mice, crossed with Rosa26-
tdTomato transgenic reporter mice (Ai14) to label
cells in which Cre-mediated recombination takes
place. Tamoxifen i.p. injections were performed at
days 1–5.
(B and C) Spinal cord samples were immuno-
stained for GFAP and S100, and the numbers of
tdTomato+ cells as well as their co-localization
with the astrocytemarker proteins were quantified.
(B) Representative images of tdTomato+ cells in
sections from control GFAPCreERT2:tdTomato
mice and mice in which the DTA expression
is additionally activated (GFAPCreERT2:DTA:
tdTomato) are shown. The insets show tdTomato+
cells with astrocytic morphology and co-localizing
with GFAP. The number of tdTomato+ astrocytes
per section were significantly reduced at day 6 in
GFAPCreERT2:DTA:tdTomato-D6 compared to
GFAPCreERT2:tdTomato-Ctrl mice. For quantifi-
cations, see (C). In (C), squares and circles repre-
sent individual mice and the bar the mean value
(n = 3/group; two-tailed Student’s t test).
(D–F) GFAPCreERT2:DTA mice were i.p. injected
with tamoxifen at days 1–5. (D) At days 5–8, mice
exhibited a severe paralysis that rapidly pro-
gressed to all four limbs and was accompanied by
weight loss (mean ± SEM; n = 3–7/group; two-way
ANOVA test). (E and F) Cervical sections were
immunostained at the indicated time points to
assess remaining astrocyte structural integrity
(S100) and to detect neurons (NeuN), oligoden-
drocytes (APC-CC1), and microglia (Iba1). Arrows
in (E) indicate neurons undergoing cell death.
For quantifications, see (F). Values of individual
mice are shown by circles (GFAPCreERT2:DTA;
n = 4–7 mice/time point) and squares (CreERT2
control tissue; n = 4). Group means are indicated
by bars. Statistical analyses were performed
via one-way ANOVA and Dunnett’s multiple
comparison test versus Ctrl. *p < 0.05; **p < 0.01;
***p < 0.001.
The scale bars represent 200 mm (B), 50 mm (inset
in B), and 50 mm (E). See also Figures S1 and S2.
1378 Cell Reports 12, 1377–1384, September 1, 2015 ª2015 The Authors
day 6 after the start of tamoxifen treatment, the expression of
DTA toxin leads to significantly reduced tdTomato+ cell numbers
compared to controls (by 73%; Figures 1B and 1C). This sug-
gested that a substantial fraction of GFAP+ astrocytes, in which
the Cre recombinase was active, were dying or in an inanimate
state with blocked (reporter) protein synthesis. i.p. injections of
tamoxifen in GFAPCreERT2:DTAmice resulted in a rapid and se-
vere paresis that started asymmetrically in both upper limbs,
later progressed to all four extremities (onset at days 5–8), and
was accompanied by weight loss (Figure 1D). In the spinal
cord, we found that the numbers of neurons (by 63%) and oligo-
dendrocytes (by 55%) were reduced at day 6, paralleling the
appearance of the clinical phenotype. In contrast, a comparable
number of S100+ astrocytes (of which only few express the Cre
recombinase and the loss of which is therefore likely obscured
by a gliotic response) was present at all time points, suggesting
that an overall astroglial support structure persisted (Figures 1E
and 1F).
The GFAPCre:iDTR mice were used to confirm the specificity
of the genetic targeting through the GFAP promoter and addi-
tionally permitted region-specific application of DT (for details,
see Figure S1). Of note, the model validated our finding that
paralysis of GFAP+ astrocytes leads to rapid and fulminant
neuronal demise. However, for the remainder of this report, we
focused on the analysis of GFAPCreERT2:DTA mice.
Neuronal Loss and Clinical Deficits Occur Independent
of Microglial Activation and Proliferation
Given the observed morphological activation and proliferation of
microglia (Figures 1E and 1F), we reasoned whether microglial-
derived factors contributed to neuronal demise and the func-
tional deficits in GFAPCreERT2:DTA mice. To directly assess
the role of microglia in astrocyte-driven motoneuron injury in
our model, we used the colony-stimulating factor 1 receptor
(CSF1R) antagonist PLX5622, which has been shown to effi-
ciently eliminate microglia from the adult brain (Elmore et al.,
2014). We conducted a 7-day treatment in control wild-type
mice and confirmed microglial depletion in isolated spinal cords
by flow cytometry (not shown). We then administered PLX5622-
containing or control chow to GFAPCreERT2:DTA mice 8 days
before tamoxifen induction (i.p. injected at days 1–5) and
throughout the experiment (Figures 2A–2C). CSFR1 blockade
decreased microglial content at day 5, as assessed by the
number of Iba1+ cells in cervical sections (by 83% in GFAP-
CreERT2:DTA and by 74% in CreERT2-control mice). However,
at the same time point, the loss in motoneuron numbers and the
severity of clinical paralysis was not significantly different from
mice fed with control chow (Figures 2B and 2C). These findings
indicate that, in our model, microglia are rather bystanders and
do not actively contribute to the initiation of neuronal injury and
clinical deficits.
Neuronal Loss after Paralysis of GFAP+ Astrocytes Does
Not Correlate with CNS Vascular Leakage or Reduction
in Glutamate-Detoxifying Enzyme Levels
A number of astrocyte properties are likely important for main-
taining neuronal health in the adult nervous system. To discern
which disturbed function of GFAP+ astrocytes is responsible
for the rapid neuronal cell loss observed in our model, we
next investigated the vascular integrity in the CNS of GFAP-
CreERT2:DTA mice (Figures S3A–S3C). Astrocytes are integral
components of the neurovascular unit, and leakage of serum
proteins has been implicated in neuronal damage (Paul et al.,
2007). Even in areas exhibiting substantial loss of neurons,
vascular basal lamina collagen-IV and endothelial glucose trans-
porter 1 (GLUT-1) (Figure S3A) expression were unaltered. We
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Figure 2. Motoneuron Loss in Spinal Cords
of GFAPCreERT2:DTA Mice Is Independent
of Microglial Bystander Activation
GFAPCreERT2:DTA (n = 9/group) and CreERT2-
control mice (n = 4 to 5/group) were pre-/treated
with the oral CSF1R inhibitor PLX5622 (1.2 g/kg
chow) or vehicle for 1 week to eliminate microglia
and kept on this diet throughout the experiment.
(A) Representative Iba1 and NeuN immunofluo-
rescent stainings from the anterior horn region
at day 5 of tamoxifen i.p. application showing loss
of moto-/neurons despite robust decreases in
microglial numbers.
(B) Quantifications of Iba1+ and motoneuron cell
bodies.
(C) There was no statistical difference in paralysis
scores at day 5 between PLX5622- and vehicle-
treated GFAPCreERT2:DTA mice.
Mice were pooled from two independent experi-
ments, and asterisks indicate significance by un-
paired Student’s t test; *p < 0.05; ***p < 0.001.
Error bars represent mean ± SEM. The scale bars
represent 100 mm (A). See also Figure S3.
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did not observe perivascular deposits of plasma-derived IgG,
even at time points when blood vessels were stripped of
GFAP+ processes (Figure S3A). Consistent with a mostly intact
neurovascular unit, there were no spontaneous microbleeds
(Figure S3A) or leukocyte extravasation (Figure S3B). We found
reduced protein contents of the tight junction component occlu-
din, which has been shown to be expressed by cultured astro-
cytes (Wachtel et al., 2001), but unaltered claudin 5 levels and
no accumulation of fibrinogen in spinal cord tissue (Figure S3C).
Whereas these data do not dismiss the importance of astrocytes
for the full functioning of the neurovascular unit, they do suggest
that neuronal injury in our model was not primarily driven by
microvascular damage and leakage of toxic blood products.
The uptake of the potentially toxic neurotransmitter glutamate
has been suggested as another important homeostatic function
of astrocytes in the CNS (Mennerick and Zorumski, 1994), and
failure to eliminate glutamate has been proposed to contribute
to several neurodegenerative disorders, such as amyotrophic
lateral sclerosis (Rothstein et al., 1995) or spinocerebellar ataxia
7 (Custer et al., 2006). We performed immunohistochemical
stainings for glutamine synthetase (GS), an astroglial enzyme
that rapidly converts excess glutamate into glutamine, in spinal
cord regions, where extensive neuronal loss could be found.
Co-labeling revealed that a considerable proportion of GS-
immunoreactive glial cells did not express GFAP in the spinal
cord area of interest (Figure S3D). Indeed, densities of GS+ cells
were unaltered compared to controls (Figures S3D and S3E)
around 1 week after the induction of GFAP+ astrocyte paralysis.
These results suggested that, despite GFAP+ astrocyte paraly-
sis, the remaining glial pool retains its capacity to detoxify gluta-
mate at least during the time period in which neuronal damage
was initiated in our model.
GFAP+ Astroglial Paralysis and Neuronal Damage Are
Associated with Decreased Capabilities to Neutralize
ROS/RNS
Reactive oxygen and nitrogen species (ROS/RNS) are another
group of potentially harmful molecules that need to be efficiently
scavenged to prevent the occurrence of oxidative stress. To
assess the redox-scavenging capacity of astrocytes, we there-
fore quantified the basal mRNA expression of ROS-detoxifying
enzymes in the glial cell population in our GFAPCreERT2:DTA
model, using the predominantly astroglial transporter GLAST
as a marker for sorting and excluding CD45lowCD11b+ microglia
cells (Figure S4). Superoxide dismutase SOD1, SOD2, and cata-
lase mRNA levels were approximately three to four times higher
in GLAST+ glia compared to microglia sorted from the CNS of
GFAPCreERT2:DTA and control mice (Figure 3A). Tamoxifen-
treatment reduced mRNA expression in GLAST+ glia by 34%
(SOD1), 47% (SOD2), or 71% (catalase). This reduction in the
glial cell pool was confirmed by intracellular protein staining for
SOD1 and SOD2 (Figure 3B). In contrast, microglial expression
of redox-scavenging enzymes was not affected (Figures 3A
and 3B). Flow cytometric analysis of GFAPCreERT2:DTA and
GFAPCreERT2 control mice crossed with the Rosa26-tdTomato
reporter mouse line confirmed that tdTomato+SOD1+ and
SOD2+ astrocytes vanished after tamoxifen treatment of GFAP-
CreERT2:DTA mice (Figure 3C). Diminished ROS-scavenging
capabilities in GFAPCreERT2:DTA mice were accompanied by
increased superoxide levels and enhanced oxidative DNA dam-
age (Figures 3D and 3E). A disturbed redox balance in our model
would also be consistent with the ultrastructural signs of
abnormal autophagic activity that we observed in degenerating
neurons (Figures 3F–3H; Scherz-Shouval et al., 2007). To eval-
uate the effect of ROS/RNS scavengers in vivo, mice were
treated i.p. with a ROS/RNS scavenger cocktail containing
FeTPPS, EUK134, and PBN starting from the day of tamoxifen
application (Nikic et al., 2011). Compared to the vehicle-treated
cohort, ROS/RNS scavenger-treated mice showed a signifi-
cantly increased number of surviving neurons including a pre-
servation of motoneurons, whereas the number of astrocytes,
oligodendrocytes, andmicroglial cells were not affected (Figures
4A and 4B). In addition, we measured serum concentrations of
neuron-specific enolase (NSE), which is systemically released
upon neuronal injury. NSE serum levels in GFAPCreERT2:DTA
mice were significantly increased compared to CreERT2 con-
trols (Figure 4C) with mean NSE levels lying between values re-
ported for models of ischemic stroke and inflammatory CNS
insults (Gelderblom et al., 2013). Again treatment with ROS/
RNS scavengers reduced serum NSE levels by approximately
75% (Figure 4C). ROS/RNS scavenging not only improved
neuronal survival but also prevented clinical deficits (at days
5 or 6; Figure 4D). Taken together, these data indicate that
neuronal damage and the resulting clinical paralysis in our model
is at least partly caused by the disturbed redox homeostasis that
results from paralysis of GFAP+ astrocytes.
DISCUSSION
Whereas it is becoming increasingly clear that astrocytes play an
important role in a number of neurological disorders, their contri-
bution to tissue homeostasis in the healthy nervous system is still
not fully understood. Here, we addressed this question by genet-
ically paralyzing and depleting GFAP+ astrocytes in adult mice
in vivo. Using this method has proven to be valuable to under-
stand the role of microglia (Parkhurst et al., 2013), mature oligo-
dendrocytes (Locatelli et al., 2012), or neuronal subpopulations
like agouti-related protein (ARP)+ neurons (Gropp et al., 2005)
in the adult CNS. In all those depletion models, the mice were
viable and displayed, if any, only subtle clinical phenotypes un-
der steady-state conditions. We set out to target and reduce
GFAP+ astrocytes, which, depending on the CNS region, com-
prise only a fraction of all astrocytes (Cahoy et al., 2008). Yet,
our results provide direct evidence that, different from other glial
cell types in the CNS, GFAP+ astrocytes are far more critical for
neuronal integrity in adult mammals.
We observed a rapid onset of severe motor deficits that
was accompanied by early neuronal injury and substantial cell
loss. This phenotype contrasts with what is observed after
induced depletion of pMN-derived AldoC+ astrocytes (Olig2-
cre:Aldh1L1-DTA; Tsai et al., 2012), where sizes and numbers
of motoneurons in spinal cord ventral horns remained unaf-
fected. This discrepancy is likely to arise from the fact that
distinct subsets of astrocytes are targeted and that there are po-
tential compensatory events in place when astroglial cells are
affected during embryonic development. Experiments aiming
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to remove certain intermediate filaments already indicated that
the full integrity of the astrocyte cytoskeleton in the absence of
further injury is largely irrelevant for neuronal survival (Colucci-
Guyon et al., 1994; Pekny et al., 1995). Our findings support
this notion, as neuronal damage in the experimental procedures
here occurred despite persistence of an astroglial support struc-
ture, in part provided by remaining GFAP astrocyte populations
and the mostly intact CNS microvasculature.
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Figure 3. Reduced Glial ROS-Scavenging Capabilities in GFAPCreERT2:DTA Mice
(A and B) The relative expression of various detoxifying enzymes of the ROS defense system were reduced in the sorted GLAST+ glial cell pool from the CNS of
GFAPCreERT2:DTA mice at days 5 to 6 compared with CreERT2- controls as determined by (A) real-time PCR analysis, (B) intracellular staining, and flow
cytometry (mean ± SEM; n = 3–6 mice/group). GPx, glutathione peroxidase.
(C) For confirmation, the absolute number of SOD+ tdTomato+ astrocytes of the CNS glial population was determined by flow cytometry using
GFAPCreERT2:DTA:tdTomato and control mice (representative sample; n = 2 per group). FMO, fluorescence minus one staining.
(D) This was accompanied by increased labeling of cervical spinal cord sections with the fluorescent ROS probe DHE or the oxidative-stress marker 8-ox-
oguanine.
(E) Quantifications of 8-oxoguanine+ nuclei (n = 3 mice/group; individual mice represented by squares and circles; average of six to seven sections/
mouse).
(F) Electron microscopy of a large dystrophic neurite containing autolysosomes and electron-dense and numerous enlarged multivesicular bodies (arrows).
(G and H) Mitochondria surrounded by membranes (arrows) indicating early autophagy.
The scale bars represent 50 mm (DHE; D), 20 mm (8-oxoguanine; D), 10 mm (zoom; D), and 200 nm (F–H). p values for unpaired comparisons were analyzed by two-
tailed Student’s t test. *p < 0.05; **p < 0.01; ***p < 0.001. See also Figure S4.
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Microglia activation is present in the vicinity of the degenerat-
ing motoneurons, for example in amyotrophic lateral sclerosis
(Troost et al., 1990). Our results show that, after astrocyte paral-
ysis, microglia respond early to disturbed CNS homeostasis and
become activated even before neuronal injury is obvious.
Although treatment with an oral CSFR1 inhibitor virtually abol-
ished microglial activation and proliferation, spinal cord moto-
neurons died and clinical paralysis developed. Even though
our findings clearly do not exclude a role of microglia in the prop-
agation of other neurodegenerative conditions, they indicate
that, in our relatively rapid model of astrocyte paralysis-induced
motoneuron death, microglia are not critical players.
What are the mechanisms of astrocyte paralysis-mediated
neuronal damage? Astrocytes synthesize a plethora of factors
that have been shown, still mostly in vitro, to be important for
neuronal and synaptic integrity (Allen et al., 2012; Christopher-
son et al., 2005). Although acute inhibition of astrocyte protein
synthesis might result in lack of trophic support for neurons, it
is equally likely that it leads to inactivation of glial-detoxifying
pathways. Mutations in SOD1 cause a rare form of familial amyo-
trophic lateral sclerosis, and studies using transgenic rodents
expressing mutant human SOD1 have indeed demonstrated
that motoneurons are particularly vulnerable to toxic activity
mediated by astrocytes (Gurney et al., 1994; Nagai et al.,
2007). Previous co-culture experiments suggested that neurons
depend on the antioxidant potential of astrocytes for their own
defense against oxidative stress in vitro (Desagher et al., 1996).
Of the potential mechanisms studied here, we found a critical
involvement of astrocytes in redox homeostasis and that the le-
sioning of adult astrocytes in vivo leads to oxidative stress and
neuronal decline.
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Figure 4. Neutralization of ROS and RNS
Rescues Neurons in GFAPCreERT2:DTA
Mice
(A and B) Glial and neuronal cell numbers after i.p.
(+) ROS/RNS scavenger or () vehicle treatment
(n = 4 to 5 mice/group). NeuN-positive neurons
and motoneurons per anterior horn were signifi-
cantly increased by ROS/RNS scavenging (nR 3
mice/group).
(C) Extent of neuronal injury quantified by serum
levels of NSE (mean ± SEM; serum from n = 8–14
mice/group).
(D) Weight and paralysis score at days 5 to 6
(clinical onset; mean ± SEM; n = 6 to 7 mice/
group).
The scale bars represent 100 mm (A). p values for
unpaired comparisons were analyzed by two-
tailed Student’s t test. *p < 0.05; **p < 0.01.
In summary, our study identifies the
redox-scavenging capacity of GFAP+ as-
trocytes as a key contributor to CNS ho-
meostasis and suggests that the pure
scaffold function of astrocytes is much
less critical to neuronal health than the
metabolic integrity of the glia-neuron
interface. From a translational viewpoint,
our findings have implications not only for neurodegenerative
diseases such as amyotrophic lateral sclerosis but also for
neuroprotective interventions that might be more likely to
succeed if they target not only neurons but also their glial
environment.
EXPERIMENTAL PROCEDURES
In Vivo Treatments
All procedures involving animals were approved by the veterinary office of the
Canton of Zurich, Switzerland. GFAPCreERT2:DTAmicewere i.p. injectedwith
a tamoxifen dosage of 2 mg/day for 5 days on a daily basis (days 1–5). To
eliminate microglia, mice were treated with the CSF1R antagonist, PLX5622
(Plexxikon), formulated in AIN-76A rodent chow (Research Diets) at a dose
of 1.2 g/kg. To scavenge ROS and/or RNS, we i.p. injected a cocktail contain-
ing FeTTPS (5,10,15,20-tetrakis(4-sulfonatophenyl)porphyrinato iron (III), chlo-
ride; Calbiochem), a peroxynitrate scavenger, PBN (N-tert-butyl-a-phenylni-
trone; Sigma-Aldrich), a spin trap that reacts with superoxide and hydroxyl
radicals, and EUK134 (Cayman Chemicals), a catalase and superoxide dis-
mutase analog, as described in detail in Nikic et al. (2011).
Clinical Scoring
Paralysis scores of GFAPCreERT2:DTA mice were assessed on a scale from
0 to 5, with 0 indicating no detectable signs, 1 paresis of one front limb, 2
paresis of two front limbs, 3 complete bilateral front limb paralysis, 3.5 com-
plete bilateral front limb paralysis and partial hind limb paralysis, 4 tetraparal-
ysis, and 5 dead. For additional details, please see the Supplemental Experi-
mental Procedures.
Immunohistochemistry, Image Acquisition, and Quantifications
Immunohistochemistry was performed following standard methods. For
further information including antibodies dilutions, clones, and/or companies,
we refer to the Supplemental Experimental Procedures. The superoxide
indicator dihydroethidium (DHE; Sigma-Aldrich) was injected at 1 mg/ml
(200 ml/mouse) i.p. or i.v. After 30–90 min, mice were intracardially perfused
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with PBS and spinal cords frozen in OCT compound prior to cryostat
sectioning and mild fixation with 2% PFA.
Images were processed and merged by Imaris imaging software (version
7.5.1; Bitplane). Cells were counted manually, or quantifications were done
automatically using Imaris or Fiji/ImageJ 1.46j (NIH) software.
Transmission Electron Microscopy
Transmission electron microscopy was performed as previously described
(Locatelli et al., 2012).
CNS Flow Cytometry
We homogenized adult brain and spinal cord tissues and removed the myelin
using a 30% Percoll gradient. For further information on cytometric analysis
including antibodies clones and/or companies, we refer to the Supplemental
Experimental Procedures. Cell sorting was carried out using a FACSAria III
(BD). The gating strategy of GLAST+ astrocyte FACS-isolation is depicted in
Figure S4. Data analysis was done using FlowJo X 10.0.7 (Treestar).
NSE ELISA
NSE concentrations were determined in serum samples using the CanAg NSE
EIA (Fujirebio) as described (Gelderblom et al., 2013).
Real-Time qPCR
Total RNA was purified from sorted cells with the RNeasy Micro kit (QIAGEN)
according to the manufacturer’s instructions. The RNA from individual, single
mice was isolated, cDNA synthesized, and real-time PCR done in triplicates
using a CFX384 Cycler (Bio-Rad). The results were normalized to those of an
internal control (DNA polymerase II), and then transcripts in each sample
were normalized to a calibrator sample.
Statistical Analysis
Statistical significance was determined with GraphPad Prism (GraphPad
Software). Unpaired two-tailed Student’s t tests or one-way ANOVA tests
with Dunnett’s multiple comparison test were performed to analyze signifi-
cance between experimental and control groups. Two-way repeated-mea-
sures ANOVA tests were used to detect interactions between time and
genotype.
For additional details, please see the Supplemental Experimental
Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and four figures and can be found with this article online at http://dx.doi.org/
10.1016/j.celrep.2015.07.051.
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